Thyroid Tumor Classification via Gene Expression Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining the behavior of thyroid tumors, such as cytological diagnosis and blood tests, face challenges in accurately distinguishing between benign and malignant tumors, particularly in cases where specificity and positive predictive value are low, leading to potential unnecessary medical treatments for benign tumors.
Innovation Solution
A system and method utilizing a processor and software to analyze the expression levels of specific gene clusters, including AIF1L, CDH16, FAM162B, FGFR2, and others, to classify thyroid tumors as benign or malignant based on measured gene expression levels, providing a more accurate determination of tumor behavior.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If cytological diagnosis is performed based on observation results of cells, then the determination of thyroid tumor behavior can be made, but the determination results vary depending on the experience and skill of the tester, leading to low specificity and positive predictive value
Solution Approach 1:
The patent replaces the mechanical/visual observation system of cytological diagnosis with a molecular biology-based detection system. Specifically, it uses detection of gene expression levels (molecular markers) to determine thyroid tumor behavior, substituting the subjective cellular observation with objective molecular measurement. This resolves the contradiction by providing both high determination accuracy and reliable, reproducible results independent of tester experience.
Solution Approach 2:
The patent changes the diagnostic parameter from cellular morphology observation to gene expression level measurement. By measuring the expression levels of specific genes (such as TTF-1, thyroglobulin, calcitonin, CEA, and other markers) in the tumor tissue, the system achieves more precise and reliable determination of thyroid tumor behavior, transforming the diagnostic approach from subjective visual assessment to objective quantitative molecular analysis.
2Reliability
If gene expression analysis is used to determine thyroid tumor behavior, then objective determination is achieved, but the specificity and positive predictive value remain very low, leading to misclassification of benign tumors as malignant
Solution Approach 1:
The patent segments the gene expression analysis into multiple specific gene markers with distinct diagnostic functions. Instead of using a single gene expression analysis, it measures the expression levels of multiple specific genes (including TTF-1, thyroglobulin for thyroid origin; calcitonin for medullary carcinoma; CEA for follicular carcinoma; and other differential markers) to create a comprehensive diagnostic profile. This segmentation allows for more precise classification and improves both specificity and positive predictive value while maintaining objectivity.
Solution Approach 2:
The patent employs a composite diagnostic approach by combining multiple gene expression markers into an integrated diagnostic system. It uses a panel of different gene markers that target various aspects of thyroid tumor pathology (thyroid origin, malignancy type, differentiation status) to create a composite diagnostic conclusion. This composite approach resolves the contradiction by achieving high specificity and positive predictive value through the synergistic use of multiple molecular indicators while maintaining the objectivity of molecular-based diagnosis.
3Adaptability or versatility
If blood test for tumor markers is performed, then thyroid carcinoma can be examined, but the tumor marker value is not always increased even when symptoms are shown, making diagnosis insufficient
Solution Approach 1:
The patent performs preliminary action by directly analyzing gene expression levels in the thyroid tumor tissue itself (obtained through fine-needle aspiration or surgical resection) rather than relying on indirect blood-based tumor marker measurements. This direct tissue analysis occurs before final diagnosis is made, allowing for accurate determination of thyroid tumor behavior regardless of whether tumor markers are elevated in the blood. The approach captures the actual molecular profile of the tumor, providing definitive diagnostic information that blood tests alone cannot provide.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention provides a system adapted to a method for determining behavior of thyroid tumor. The system comprises a processor, and a memory, under control of said processor, including software instructions adapted to enable the system to perform operations.